v3.24.3
Summary of Significant Accounting Policies - Schedule of Disaggregation of Total Product Sales (Details) - USD ($)
$ in Thousands
 3 Months Ended 9 Months Ended
Sep. 30, 2024
Sep. 30, 2023
Sep. 30, 2024
Sep. 30, 2023
Summary Of Significant Accounting Policies [Line Items]        
Total revenue $ 90,377 $ 47,725 $ 237,474 $ 116,820
Livmarli        
Summary Of Significant Accounting Policies [Line Items]        
Total revenue 59,126 38,708 149,202 100,303
Bile Acid Medicines        
Summary Of Significant Accounting Policies [Line Items]        
Total revenue 31,176 9,017 87,777 9,017
Total product sales, net        
Summary Of Significant Accounting Policies [Line Items]        
Total revenue 90,302 47,725 236,979 109,320
License and other revenue        
Summary Of Significant Accounting Policies [Line Items]        
Total revenue $ 75 $ 0 $ 495 $ 7,500